Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP
Objective: Currently, <sup>68</sup>Ga-labeled somatostatin analogs (SSAs) are the most commonly used imaging agents for patients with neuroendocrine tumors (NETs) in clinical practice, demonstrating good results in tumor diagnosis. For applications in peptide receptor radionuclide therap...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/12/1647 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037154889072640 |
|---|---|
| author | Huanhuan Liu Xiaojun Zhang Yue Pan Jingfeng Zhang Hui Wen Cong Zhang Xiaodan Xu Guangyu Ma Ruimin Wang Jinming Zhang |
| author_facet | Huanhuan Liu Xiaojun Zhang Yue Pan Jingfeng Zhang Hui Wen Cong Zhang Xiaodan Xu Guangyu Ma Ruimin Wang Jinming Zhang |
| author_sort | Huanhuan Liu |
| collection | DOAJ |
| description | Objective: Currently, <sup>68</sup>Ga-labeled somatostatin analogs (SSAs) are the most commonly used imaging agents for patients with neuroendocrine tumors (NETs) in clinical practice, demonstrating good results in tumor diagnosis. For applications in peptide receptor radionuclide therapy (PRRT), targeted drugs should have high tumor uptake and prolonged tumor retention time. To enhance the uptake and retention of tracers in NETs, our goal is to design a <sup>68</sup>Ga-labeled heterodimer for optimizing pharmacokinetics and assess whether this form is more efficacious than its monomeric equivalents. Methods: Using the somatostatin analog TATE and quinoline-based compound FAPI-46 as raw materials, we designed and synthesized <sup>68</sup>Ga-labeled TATE-46. The labeling efficiency and stability were verified by Radio-HPLC. The receptor binding properties and tumor targeting were examined both in vitro and in vivo by using NCI-H727 (SSTR2/FAP, positive) and Mc38 (SSTR2/FAP, negative) cell lines and tumor-bearing mouse models. Preclinical evaluation was performed through cell uptake, pharmacokinetics, Micro PET, and biodistribution studies, and the results were compared with [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga -FAPI-46. Immunohistochemistry and HE staining were performed on tumor tissues from tumor-bearing mice for further validation. Results: [<sup>68</sup>Ga]Ga-TATE-46 showed comparable SSTR2 and FAP targeting ability to monomeric TATE and FAPI-46 in cell uptake and PET imaging studies. [<sup>68</sup>Ga]Ga-TATE-46 exhibited significantly higher uptake in NCI-H727 (SSTR2/FAP, positive) tumors compared to [<sup>68</sup>Ga]Ga-DOTA-TATE (<i>p</i> < 0.001) and [<sup>68</sup>Ga]Ga-FAPI-46 (<i>p</i> < 0.001). No increased uptake of [<sup>68</sup>Ga]Ga-TATE-46 was observed in MC38 tumors (SSTR2/FAP, negative). Additionally, excess DOTA-TATE and/or unlabeled FAPI-46 significantly blocked the uptake of [<sup>68</sup>Ga]Ga-TATE-46 in NCI-H727 tumors (<i>p</i> < 0.001), confirming its dual-receptor targeting characteristics. The ex vivo biodistribution, immunofluorescence and immunohistochemistry results were in line with the in vivo imaging findings. Conclusion: Compared with <sup>68</sup>Ga-labeled FAPI-46 and DOTA-TATE mono-specific tracers, the dual-target tracer [<sup>68</sup>Ga]Ga-TATE-46 improves tumor uptake, extends tumor retention, and enhances pharmacokinetics. It is an effective probe for non-invasive detection of tumors expressing FAP and SSTR2, and it is worth further studying its application in the expression of sstr2 and FAP-related tumors. |
| format | Article |
| id | doaj-art-cb7e10595e7b405dba4a770bb84efa10 |
| institution | DOAJ |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-cb7e10595e7b405dba4a770bb84efa102025-08-20T02:56:57ZengMDPI AGPharmaceuticals1424-82472024-12-011712164710.3390/ph17121647Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAPHuanhuan Liu0Xiaojun Zhang1Yue Pan2Jingfeng Zhang3Hui Wen4Cong Zhang5Xiaodan Xu6Guangyu Ma7Ruimin Wang8Jinming Zhang9Department of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaDepartment of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Beijing 100853, ChinaObjective: Currently, <sup>68</sup>Ga-labeled somatostatin analogs (SSAs) are the most commonly used imaging agents for patients with neuroendocrine tumors (NETs) in clinical practice, demonstrating good results in tumor diagnosis. For applications in peptide receptor radionuclide therapy (PRRT), targeted drugs should have high tumor uptake and prolonged tumor retention time. To enhance the uptake and retention of tracers in NETs, our goal is to design a <sup>68</sup>Ga-labeled heterodimer for optimizing pharmacokinetics and assess whether this form is more efficacious than its monomeric equivalents. Methods: Using the somatostatin analog TATE and quinoline-based compound FAPI-46 as raw materials, we designed and synthesized <sup>68</sup>Ga-labeled TATE-46. The labeling efficiency and stability were verified by Radio-HPLC. The receptor binding properties and tumor targeting were examined both in vitro and in vivo by using NCI-H727 (SSTR2/FAP, positive) and Mc38 (SSTR2/FAP, negative) cell lines and tumor-bearing mouse models. Preclinical evaluation was performed through cell uptake, pharmacokinetics, Micro PET, and biodistribution studies, and the results were compared with [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga -FAPI-46. Immunohistochemistry and HE staining were performed on tumor tissues from tumor-bearing mice for further validation. Results: [<sup>68</sup>Ga]Ga-TATE-46 showed comparable SSTR2 and FAP targeting ability to monomeric TATE and FAPI-46 in cell uptake and PET imaging studies. [<sup>68</sup>Ga]Ga-TATE-46 exhibited significantly higher uptake in NCI-H727 (SSTR2/FAP, positive) tumors compared to [<sup>68</sup>Ga]Ga-DOTA-TATE (<i>p</i> < 0.001) and [<sup>68</sup>Ga]Ga-FAPI-46 (<i>p</i> < 0.001). No increased uptake of [<sup>68</sup>Ga]Ga-TATE-46 was observed in MC38 tumors (SSTR2/FAP, negative). Additionally, excess DOTA-TATE and/or unlabeled FAPI-46 significantly blocked the uptake of [<sup>68</sup>Ga]Ga-TATE-46 in NCI-H727 tumors (<i>p</i> < 0.001), confirming its dual-receptor targeting characteristics. The ex vivo biodistribution, immunofluorescence and immunohistochemistry results were in line with the in vivo imaging findings. Conclusion: Compared with <sup>68</sup>Ga-labeled FAPI-46 and DOTA-TATE mono-specific tracers, the dual-target tracer [<sup>68</sup>Ga]Ga-TATE-46 improves tumor uptake, extends tumor retention, and enhances pharmacokinetics. It is an effective probe for non-invasive detection of tumors expressing FAP and SSTR2, and it is worth further studying its application in the expression of sstr2 and FAP-related tumors.https://www.mdpi.com/1424-8247/17/12/1647somatostatin receptor 2fibroblast activation proteinPETheterodimer |
| spellingShingle | Huanhuan Liu Xiaojun Zhang Yue Pan Jingfeng Zhang Hui Wen Cong Zhang Xiaodan Xu Guangyu Ma Ruimin Wang Jinming Zhang Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP Pharmaceuticals somatostatin receptor 2 fibroblast activation protein PET heterodimer |
| title | Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP |
| title_full | Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP |
| title_fullStr | Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP |
| title_full_unstemmed | Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP |
| title_short | Preclinical Study of a Dual-Target Molecular Probe Labeled with <sup>68</sup>Ga Targeting SSTR2 and FAP |
| title_sort | preclinical study of a dual target molecular probe labeled with sup 68 sup ga targeting sstr2 and fap |
| topic | somatostatin receptor 2 fibroblast activation protein PET heterodimer |
| url | https://www.mdpi.com/1424-8247/17/12/1647 |
| work_keys_str_mv | AT huanhuanliu preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT xiaojunzhang preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT yuepan preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT jingfengzhang preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT huiwen preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT congzhang preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT xiaodanxu preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT guangyuma preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT ruiminwang preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap AT jinmingzhang preclinicalstudyofadualtargetmolecularprobelabeledwithsup68supgatargetingsstr2andfap |